<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordsOutput><serviceExecutionTime>362</serviceExecutionTime><Drug id="100134"><DrugName>benznidazole (Chagas disease), Humanigen</DrugName><DrugNamesKey><Name id="42818845">benznidazole</Name></DrugNamesKey><DrugSynonyms><Name><Value>benznidazole</Value><Types><Type>USAN</Type><Type>INN</Type></Types></Name><Name><Value>HWP-002</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>benznidazole (Chagas disease), Savant Neglected diseases</Value></Name><Name><Value>benznidazole (Chagas disease), KaloBios</Value></Name><Name><Value>benznidazole (Chagas disease), Humanigen</Value></Name><Name><Value>22994-85-0</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="1071868">Savant HWP Inc</CompanyOriginator><CompaniesSecondary><Company id="1071868">Savant HWP Inc</Company><Company id="1117016">Savant Neglected Diseases LLC</Company><Company id="31508">Humanigen Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="1071868" type="Company"><TargetEntity id="5037650358" type="organizationId">Savant HWP Inc</TargetEntity></SourceEntity><SourceEntity id="31508" type="Company"><TargetEntity id="4297292034" type="organizationId">Humanigen Inc</TargetEntity></SourceEntity><SourceEntity id="335" type="ciIndication"><TargetEntity id="B57" type="ICD10"/><TargetEntity id="D014355" type="MeSH"/><TargetEntity id="-1708981827" type="omicsDisease"/><TargetEntity id="1599" type="siCondition"/></SourceEntity><SourceEntity id="2638" type="Action"><TargetEntity id="4959" type="Mechanism">Drugs Targeting Parasite Proteins</TargetEntity><TargetEntity id="4622" type="Mechanism">Drugs Targeting Plasmodium falciparum Proteins</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="CU">Clinical</PhaseTerminated><RegulatoryDesignations><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsSecondary><Indication id="335">Trypanosoma cruzi infection</Indication></IndicationsSecondary><ActionsSecondary><Action id="59620">Unspecified drug target</Action><Action id="2638">Antiparasitic</Action></ActionsSecondary><Technologies><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><EphmraCodes><Ephmra><Code>P</Code><Name>PARASITOLOGY</Name></Ephmra></EphmraCodes><LastModificationDate>2018-12-07T12:16:23.000Z</LastModificationDate><ChangeDateLast>2017-08-09T00:00:00.000Z</ChangeDateLast><AddedDate>2015-12-08T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="31508" linkType="Company"&gt;Humanigen&lt;/ulink&gt; (previously KaloBios Pharmaceuticals), through asset acquisition from &lt;ulink linkID="1117016" linkType="Company"&gt;Savant Neglected Diseases&lt;/ulink&gt;, was developing an oral  formulation of &lt;ulink linkID="52081" linkType="Drug"&gt;benznidazole&lt;/ulink&gt; (presumed to be HWP-002), for the potential  treatment of Trypanosoma cruzi infection (Chagas disease) [&lt;ulink linkID="1718206" linkType="Reference"&gt;1718206&lt;/ulink&gt;], [&lt;ulink linkID="1718632" linkType="Reference"&gt;1718632&lt;/ulink&gt;], [&lt;ulink linkID="1916446" linkType="Reference"&gt;1916446&lt;/ulink&gt;], [&lt;ulink linkID="1951205" linkType="Reference"&gt;1951205&lt;/ulink&gt;]. In August 2017, enrollment and follow-up of subjects in a  bioavailability study was completed [&lt;ulink linkID="1951764" linkType="Reference"&gt;1951764&lt;/ulink&gt;]. However, by September 2018, the drug was no longer listed on Humanigen's pipeline [&lt;ulink linkID="2076545" linkType="Reference"&gt;2076545&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;In November 2015, a NDA filing was expected in 2016 [&lt;ulink linkID="1718206" linkType="Reference"&gt;1718206&lt;/ulink&gt;], [&lt;ulink linkID="1718632" linkType="Reference"&gt;1718632&lt;/ulink&gt;]. In December 2015, the company planned to register the drug  with the US FDA. The company  also planned to  file for FDA Priority Review Voucher (PRV)  [&lt;ulink linkID="1721382" linkType="Reference"&gt;1721382&lt;/ulink&gt;]. In December 2016, the company   completed a face-to-face meeting with the US FDA to review its proposed development plans for benznidazole. FDA's Division of Anti-Infective Products addressed the company's questions and provided guidance on preparation of an acceptable package for benznidazole [&lt;ulink linkID="1884520" linkType="Reference"&gt;1884520&lt;/ulink&gt;]. In January 2017, Humanigen reported positive guidance  from the   meeting with FDA. The  proposed 505(b)(2) approach was acceptable to FDA and if approved as a treatment for Chagas disease, benznidazole was   expected to be eligible for a PRV  [&lt;ulink linkID="1890507" linkType="Reference"&gt;1890507&lt;/ulink&gt;]. In April 2017, an NDA   was planned to    be submitted to the US FDA in the first quarter of 2018 [&lt;ulink linkID="1916446" linkType="Reference"&gt;1916446&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2015, Humanigen planned to file for Orphan Drug and Fast Track designation [&lt;ulink linkID="1718206" linkType="Reference"&gt;1718206&lt;/ulink&gt;], [&lt;ulink linkID="1718632" linkType="Reference"&gt;1718632&lt;/ulink&gt;]. In July 2017, the US FDA granted Orphan designation to benznidazole for the treatment of Chagas disease [&lt;ulink linkID="1944380" linkType="Reference"&gt;1944380&lt;/ulink&gt;], [&lt;ulink linkID="1948214" linkType="Reference"&gt;1948214&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In August 2017, Humanigen had completed enrollment and follow-up of subjects in a  bioavailability study. At that time, preliminary interpretation of the data and  final study report were expected in October and in the fourth quarter of 2017 respectively [&lt;ulink linkID="1951764" linkType="Reference"&gt;1951764&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2017, an IND application was planned to    be submitted to the US FDA in May 2017 [&lt;ulink linkID="1916446" linkType="Reference"&gt;1916446&lt;/ulink&gt;]. In May 2017, an IND was filed to the US FDA   [&lt;ulink linkID="1932783" linkType="Reference"&gt;1932783&lt;/ulink&gt;]. Later that month, the FDA accepted the IND; in June 2017, the IND became effective [&lt;ulink linkID="1941407" linkType="Reference"&gt;1941407&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In November 2015, Humanigen planned to initiate pharmacokinetic, CMC and toxicology studies in  2015/2016   [&lt;ulink linkID="1718206" linkType="Reference"&gt;1718206&lt;/ulink&gt;], [&lt;ulink linkID="1718632" linkType="Reference"&gt;1718632&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2013, development of HWP-002 by Savant was ongoing [&lt;ulink linkID="1464433" linkType="Reference"&gt;1464433&lt;/ulink&gt;]. In January 2015, development was ongoing [&lt;ulink linkID="1686109" linkType="Reference"&gt;1686109&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="31508">Humanigen Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="335">Trypanosoma cruzi infection</Indication><StatusDate>2018-09-25T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1117016">Savant Neglected Diseases LLC</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="335">Trypanosoma cruzi infection</Indication><StatusDate>2015-12-03T00:00:00.000Z</StatusDate><Source id="1718206" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1117016">Savant Neglected Diseases LLC</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="335">Trypanosoma cruzi infection</Indication><StatusDate>2015-12-03T00:00:00.000Z</StatusDate><Source id="1718206" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1071868">Savant HWP Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="335">Trypanosoma cruzi infection</Indication><StatusDate>2013-08-13T00:00:00.000Z</StatusDate><Source id="1464433" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="31508">Humanigen Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="335">Trypanosoma cruzi infection</Indication><StatusDate>2015-12-03T00:00:00.000Z</StatusDate><Source id="1718206" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="31508">Humanigen Inc</Company><Country id="US">US</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="335">Trypanosoma cruzi infection</Indication><StatusDate>2017-08-08T00:00:00.000Z</StatusDate><Source id="1951764" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><OwnerCompany id="31508">Humanigen Inc</OwnerCompany><Country id="US">US</Country><Indication id="335">Trypanosoma cruzi infection</Indication><AwardedIndication>Treatment of Chagas Disease</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="3">Filed</DesignationApplicationStatus><MileStoneDate>2015-12-03T00:00:00.000Z</MileStoneDate><Source id="1718206" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="31508">Humanigen Inc</OwnerCompany><Country id="US">US</Country><Indication id="335">Trypanosoma cruzi infection</Indication><AwardedIndication>Treatment of Chagas disease</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2017-07-05T00:00:00.000Z</MileStoneDate><Source id="1944380" type="PR"/></Row></RegulatoryDesignationStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1071868">Savant HWP Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="31508">Humanigen Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="14">Drug - Asset Divestment</Type><CountActive>0</CountActive><CountInactive>1</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>c1ccc(cc1)CNC(=O)Cn2ccnc2[N+](=O)[O-]</Smiles></StructureSmiles><Deals><Deal id="157478" title="KaloBios acquires worldwide rights of Savant's benznidazole for Chagas disease                            "/></Deals><hasSWOTs>N</hasSWOTs></Drug></drugRecordsOutput>